Bill > HR3731

This bill creates a special exception for small biotech manufacturers in the Medicare drug price negotiation program, starting in 2029. Under this legislation, a small biotech manufacturer can be exempt from drug price negotiations if they meet specific criteria: they must have 5 or fewer qualifying single-source drugs, not be owned by a foreign government, and invest a significant percentage of their net revenue (ranging from 30% to 70%, depending on the number of drugs) into research and development. To qualify for the exemption, manufacturers must submit an annual application to the Secretary of Health and Human Services, providing detailed information about their revenue and research spending. The bill includes provisions to prevent larger companies from exploiting this exemption by stipulating that if a small biotech manufacturer is acquired by a larger company that doesn't meet the research-intensive criteria, the drug would lose its exemption. Additionally, the bill establishes a dispute resolution process for manufacturers who disagree with the government's determination of their status. The overall aim is to protect and incentivize innovative small biotech companies by shielding their drugs from Medicare price negotiations.

Business and Industry

https://www.congress.gov/bill/119th-congress/house-bill/3731/all-info